ERBB2 and neoplasm: On the other hand, and in light of a recent study reporting an association between PD-L1+ TAM and poor response to trastuzumab in HER2+ BC patients (32), our observations on the marked reduction of PD-L1-expressing myeloid cells support the hypothesis of the induction of a tumor immune microenvironment favorable for clinical response and tumor regression.